June 25, 2018:

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

June 18, 2018:

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

April 20, 2018:

Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission

March 27, 2018

Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis

March 21, 2018:

Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis

December 11, 2017:

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

November 1, 2017:

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

July 17, 2017:

Fortress Biotech Announces Filing of Provisional Application for Caelum Biosciences’ CAEL-101 

June 1, 2017:

Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon

May 4, 2017:

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

April, 5, 2017:

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

January 4, 2017:

Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis